Compare Abeona Therapeutics Inc (ABEO) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X Robotics and Artificial Intelligence ETF — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Global X Robotics and Artificial Intelligence ETF trades at $36.01. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BOTZ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $41.63 |
52-Week Low | $4.17 | $31.99 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BOTZ trades at $36.59, down 2.14% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, benefiting from reshoring trends and AI's expansion into physical automation. Recent news highlights robotics as the next trillion-dollar AI theme, with strong media coverage positioning BOTZ as a key player in the humanoid robotics and industrial automation space.
Outlook remains positive due to structural growth in robotics and AI, though valuation metrics are unavailable. Risks include sector concentration and reliance on AI adoption pace. Analyst sentiment is generally favorable, with the ETF well-positioned for long-term automation trends but vulnerable to tech sector volatility and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
